The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic
The Europe Companion Diagnostics Market would witness market growth of 18.1% CAGR during the forecast period (2019-2025).
Companion diagnostics is an in vitro medical device which offers essential information for safe and effective use of a biological output or a corresponding drug. The test also helps healthcare professionals to decide if a certain therapy product is beneficial to patients and can tackle any possible severe side effects. The development of the companion diagnostics industry will be stepping up with increasing cases of adverse drug reaction (ADR). Due to the incompatibility of certain patients with conventional treatment, adverse drug reactions occur and may cause life-threatening results. However, elevated costs of companion diagnostics can to some extent hinder business growth.
Increased R&D of focused therapies, increasing demand for the personalized medication in developing markets, and the identification of new biomarkers under multiple circumstances in addition to a larger amount of unmet cancer therapy requirements, are altogether pushing the market towards exponential growth during the forecast period.
Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
Scope of the Study
- Polymerase chain reaction (PCR)
- Next generation sequencing (NGS)
- In Situ Hybridization and
- Other Technology
- Neurology and
- Other Indications
By Cancer Type
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer and
- Other Cancer Type
- Rest of Europe
- Agilent Technologies, Inc.
- Almac Group
- ARUP Laboratories, Inc.
- Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
- Danaher Corporation
- Thermo Fisher Scientific, Inc.
- Hologic, Inc.
- Novartis AG
- Illumina, Inc.
- Qiagen N.V.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free